Deliver Your News to the World

Epigenomics AG Pursuing Development of Tamoxifen Response Test


Monday, 30.01.2006, erlin, Germany and Seattle, WA, USA, Epigenomics AG (Frankfurt, Prime Standard: ECX), a molecular diagnostics company developing tests based on DNA methylation, announced today that Roche Diagnostics will return full rights for a Tamoxifen treatment response and breast cancer molecular classification test to Epigenomics, which will undertake sole development of the test. This tissue-based test, designed to predict the probability of disease recurrence in breast cancer patients, was part of a multi-product collaboration with Roche Diagnostics. Epigenomics and Roche Diagnostics will continue to collaborate on the development of three screening products for colon, prostate and breast cancers.

“Epigenomics’ proprietary product strategy is now well on track as it focuses on tissue-based molecular pathology tests for high margin specialty applications in oncology. Now that we have sole rights to both breast and the prostate cancer molecular classification tests, which are highly synergistic in product development as they are partly based on the same biomarkers, we have two products that spearhead this strategy and form a solid basis for our own development pipeline,” noted Alex Olek, CEO of Epigenomics.

Today, Monday, January 30, 2006, Epigenomics’ management will host a conference call at 2.00 PM/CET. The dial-in number for the call is:

+49 (0)69 58 999 0808 for European participants, and
+1 480 629 9564 for US participants.

About Epigenomics
Epigenomics is a molecular diagnostics company with a focus on the development of novel products for cancer. By detecting and interpreting DNA methylation patterns, Epigenomics’ tests can potentially diagnose disease at an early stage and help guide physicians to select an appropriate therapy. Epigenomics collaborates with Roche Diagnostics on the development of several diagnostic products in cancer. The company has its headquarters in Berlin, Germany, and a wholly owned subsidiary in Seattle, USA. For more information, please visit our website at

# # #

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.